Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

INO holding history

Inovio Pharmaceuticals, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

INO overviewAll 13F holders of INOFull Q2 2026 holdings

Shares (Q2 2026)
262,320
Value
$288.6K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of INO by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026262,320$288.6K<0.1%+12,670+5.1%AddedHolders
Q1 2026249,650$434.4K<0.1%+79,071+46.4%AddedHolders
Q4 2025170,579$296.8K<0.1%−122,483−41.8%ReducedHolders
Q3 2025293,062$685.8K<0.1%+93,383+46.8%AddedHolders
Q2 2025199,679$406.3K<0.1%−8,188−3.9%ReducedHolders
Q1 2025207,867$338.8K<0.1%+30,893+17.5%AddedHolders
Q4 2024176,974$323.9K<0.1%+163,259+1,190.4%AddedHolders
Q3 202413,715$79.3K<0.1%−13,676−49.9%ReducedHolders
Q2 202427,391$221.3K<0.1%+25,475+1,329.6%AddedHolders
Q1 20241,916$26.6K<0.1%−2,457−56.2%ReducedConverted for a 1-for-12 splitHolders
Q4 202352,475$26.8K<0.1%−2,635−4.8%ReducedHolders
Q3 202355,110$21.4K<0.1%+47,992+674.2%AddedHolders
Q2 20237,118$3.18K<0.1%−791,994−99.1%ReducedHolders
Q1 2023799,112$655.3K<0.1%−117,528−12.8%ReducedHolders
Q4 2022916,640$1.43M<0.1%+614,013+202.9%AddedHolders
Q3 2022302,627$522.0K<0.1%−301,618−49.9%ReducedHolders
Q2 2022604,245$1.05M<0.1%−1,035,767−63.2%ReducedHolders
Q1 20221,640,012$5.89M<0.1%+817,297+99.3%AddedHolders
Q4 2021822,715$4.11M<0.1%+365,577+80.0%AddedHolders
Q3 2021457,138$3.27M<0.1%+360,844+374.7%AddedHolders
Q2 202196,294$892.0K<0.1%−11,747−10.9%ReducedHolders
Q1 2021108,041$1.00M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.